Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Aplastic anemia (AA) is a rare bone marrow failure disease characterized by bone marrow
hypocellularity and peripheral blood pancytopenia. AA is divided into severe AA (SAA) and
non-severe AA (NSAA) based on the degree of cytopenia. The first line therapy for SAA or
transfusion dependent NSAA is either immunosuppression therapy (IST) or hematopoietic stem
cell transplantation (HSCT). Little attention has been paid to patients with anemia but not
transfusion dependent, whose quality of life is significantly impaired due to the anemia and
other complications.